Mesothelioma and Radical Surgery 2 (MARS 2): protocol for a multicentre randomised trial comparing (extended) pleurectomy decortication versus no (extended) pleurectomy decortication for patients with malignant pleural mesothelioma

INTRODUCTION: Mesothelioma remains a lethal cancer. To date, systemic therapy with pemetrexed and a platinum drug remains the only licensed standard of care. As the median survival for patients with mesothelioma is 12.1 months, surgery is an important consideration to improve survival and/or quality...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:BMJ Open
Hauptverfasser: Lim, Eric, Darlison, Liz, Edwards, John, Elliott, Daisy, Fennell, D A, Popat, Sanjay, Rintoul, Robert C, Waller, David, Ali, Clinton, Bille, Andrea, Fuller, Liz, Ionescu, Andreea, Keni, Manjusha, Kirk, Alan, Koh, Pek, Lau, Kelvin, Mansy, Talal, Maskell, Nick A, Milton, Richard, Muthukumar, Dakshinamoorthy, Pope, Tony, Roy, Amy, Shah, Riyaz, Shamash, Jonathan, Tasigiannopoulos, Zacharias, Taylor, Paul, Treece, Sarah, Ashton, Kate, Harris, Rosie, Joyce, Katherine, Warnes, Barbara, Mills, Nicola, Stokes, Elizabeth A, Rogers, Chris
Format: Artigo
Sprache:Inglês
Veröffentlicht: BMJ Publishing Group 2020
Schlagworte:
Oncology
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7467531/
https://ncbi.nlm.nih.gov/pubmed/32873681
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bmjopen-2020-038892
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge